Abstract
Peripheral μ-, k- and δ-opioid agonist trimebutine maleate is considered to be an effective therapeutic drug for the treatment of functional gastrointestinal disorders. Ninety-two paediatric outpatients (12- 17 year-old) suffering from functional dyspepsia (epigastric pain and meal-induced dyspeptic symptoms) were enrolled in a prospective openlabel study. For ethical reasons, no placebo group was included. Patients were treated with trimebutine maleate (200 mg three times daily). After a 3-week treatment there was a significant decrease in scores of epigastric pain (p<0.05), postprandial fullness (p<0.05), early satiety (p<0.05), nausea (p<0.05) and belching (p<0.05). The treatment regimen was well tolerated and demonstrated a good compliance. In conclusion, we postulate that trimebutine maleate is an effective medication for relief of main symptoms associated with functional dyspepsia syndrome in childhood. Because of the limited data on therapeutic interventions in functional dyspepsia in childhood and increasing demand for therapies to treat this disorder, further evaluation of the efficacy of trimebutine treatment for children is certain. DOI: http://dx.doi.org/10.3126/jnps.v33i2.7229 J Nepal Paediatr Soc. 2013; 33(2):158-162
Highlights
Paediatric functional gastrointestinal disorders in childhood include a combination of chronic or recurrent symptoms and are not explained by structural or biochemical abnormalities[1]
We postulate that trimebutine maleate is an effective medication for relief of main symptoms associated with functional dyspepsia syndrome in childhood
The best results were obtained in resolution of epigastric pain, postprandial fullness and early satiety, nausea and belching (p
Summary
Paediatric functional gastrointestinal disorders in childhood include a combination of chronic or recurrent symptoms and are not explained by structural or biochemical abnormalities[1]. The Rome III committee defined FD as the presence of complex of symptoms including epigastric pain and meal-induced dyspeptic symptoms, comprising a large number of non-painful symptoms (postprandial fullness, early satiety, abdominal bloating, belching and postprandial nausea) in the absence of any organic, systemic or metabolic disease that may explain the symptoms. Any combination of these symptoms may intermittently occur over time[4]. Over 50% of dyspeptic patients in childhood alongside with RAP suffered from nausea, vomiting, bloating, early satiety and nocturnal awakening[2,5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
